PHARMACEUTICAL PRODUCTS EXCLUDING SURGICAL IMPLANTS

Brand Owner Address Description
STEMCIS STEMCIS Cyclotron Réunion Océan Indien Cytrol 2 rue Maxime Rivière SAINTE-CLOTILDE F97490 France Pharmaceutical products excluding surgical implants comprising living tissue, namely, pharmaceutical products comprised of adipose tissue, adipose stem cells and progenitor cells for use in plastic and reconstructive surgery and human regenerative medicine; veterinary products excluding surgical implants comprising living tissue, namely, adipose tissue, adipose stem cells and progenitor cells; chemical preparations comprised of adipose tissue, adipose stem cells and progenitor cells for medical use and pharmaceutical use;Medical services relating to therapeutic solutions in the fields of plastic and reconstructive surgery and human regenerative medicine, using adipose tissue and progenitor cells, excluding implants; medical consultation; plastic surgery relating to therapeutic solutions by using adipose tissue and progenitor cells, excluding implants; hospital services relating to therapeutic solutions by using adipose tissue and progenitor cells, excluding implants; alternative medicine services;Surgical apparatus and instruments for collecting adipose tissue and purifying cells, excluding implants; medical apparatus and instruments for collecting adipose tissue and purifying cells, excluding implants; veterinary apparatus and instruments for collecting adipose tissue and purifying cells, excluding implants;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. A system for implanting a surgical device to control the circumference of internal anatomic passages corrects physiologic dysfunctions resulting from a structural lumen which is either too large or too small. Implants are disclosed which employ various means for adjusting and maintaining the size of an orifice to which they are attached. Systems permit the implants to be implanted using minimally invasive procedures and permit final adjustments to the circumference of the implants after the resumption of normal flow of anatomic fluids in situ. Methods are disclosed for using the implants to treat heart valve abnormalities, gastroesophageal abnormalities, anal incontinence, and the like.